LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

Home・Akciju saraksts・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

98.73 2.66

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

94.62

Max

99.13

Galvenie mērījumi
By Trading Economics
Ienākumi	-6.3M -53M
Pārdošana	2.8M 51M
EPS	-0.82
Peļņas marža	-103.131
Darbinieki	283
EBITDA	-7.6M -48M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+49.37% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 26. febr.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-1.1B 6.4B
Iepriekšējā atvēršanas cena	96.07
Iepriekšējā slēgšanas cena	98.73

Ziņu noskaņojums

By Acuity

64%

36%

126 / 351 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

60 / 65.58 Atbalsts un pretestība

Rhythm Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 24. febr. 23:07 UTC

Peļņas

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

2026. g. 24. febr. 23:01 UTC

Peļņas

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

2026. g. 24. febr. 22:59 UTC

Peļņas

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

2026. g. 24. febr. 22:42 UTC

Peļņas

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

2026. g. 24. febr. 22:24 UTC

Iegādes, apvienošanās, pārņemšana

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

2026. g. 24. febr. 23:46 UTC

Tirgus saruna

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

2026. g. 24. febr. 23:36 UTC

Tirgus saruna

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

2026. g. 24. febr. 23:30 UTC

Tirgus saruna

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

2026. g. 24. febr. 23:20 UTC

Tirgus saruna

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

2026. g. 24. febr. 23:20 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 24. febr. 23:16 UTC

Peļņas

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

2026. g. 24. febr. 23:13 UTC

Peļņas

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

2026. g. 24. febr. 23:12 UTC

Peļņas

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

2026. g. 24. febr. 23:10 UTC

Peļņas

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

2026. g. 24. febr. 23:10 UTC

Peļņas

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

2026. g. 24. febr. 23:08 UTC

Peļņas

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

2026. g. 24. febr. 23:07 UTC

Peļņas

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

2026. g. 24. febr. 22:52 UTC

Peļņas

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

2026. g. 24. febr. 22:46 UTC

Peļņas

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

2026. g. 24. febr. 22:31 UTC

Iegādes, apvienošanās, pārņemšana

Warner Receives New Bid From Paramount -- 3rd Update

2026. g. 24. febr. 22:29 UTC

Peļņas

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

2026. g. 24. febr. 22:28 UTC

Peļņas

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

2026. g. 24. febr. 22:27 UTC

Peļņas

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

2026. g. 24. febr. 22:27 UTC

Peļņas

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

2026. g. 24. febr. 22:25 UTC

Peļņas

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

2026. g. 24. febr. 22:24 UTC

Peļņas

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

2026. g. 24. febr. 22:23 UTC

Peļņas

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

2026. g. 24. febr. 22:22 UTC

Peļņas

Woolworths Interim Dividend 45 Australian Cents/Share

2026. g. 24. febr. 22:22 UTC

Peļņas

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

2026. g. 24. febr. 22:21 UTC

Peļņas

Woolworths 1H Statutory Net Profit A$374 Mln, Down 49.4%

Salīdzinājums

Cenas izmaiņa

Rhythm Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

49.37% augšup

Prognoze 12 mēnešiem

Vidējais 143.92 USD 49.37%

Augstākais 167 USD

Zemākais 125 USD

Pamatojoties uz 14 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Rhythm Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

14 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 14 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Rhythm Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

60 / 65.58Atbalsts un pretestība

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Noskaņojums

By Acuity

126 / 351 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.